AbbVie Inc. (abbv)
ABBV — Company Overview
Investors tracking ABBV follow a Drug Manufacturers - General name listed on NYQ within Healthcare.
| Ticker | ABBV |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Exchange | NYQ |
| Market cap | $468.43B |
| Last price | $265.08 |
| Size category | Mega Cap |
ABBV — Business Description
The business profile of AbbVie Inc. (ABBV) reflects its role in Drug Manufacturers - General. AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection t…
Official website: https://www.abbvie.com.
ABBV — Investment Thesis
AbbVie Inc. (ABBV) attracts investors weighing Drug Manufacturers - General fundamentals against current market pricing.
- Revenue is expanding at roughly 10.2% year-over-year (public data).
- Trailing P/E of 75.09× implies elevated growth expectations at the current price.
- Forward P/E (16.30×) is below trailing P/E — earnings may be expected to improve.
- Dividend yield near 2.6% adds an income component to total return.
- Equity market capitalization is approximately $468.43B.
See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.
ABBV — Financial Health
ABBV financial profile reflects operating efficiency and capital structure using available market fundamentals.
Profit margin near 9.8% leaves a narrower cushion versus higher-margin peers. Positive free cash flow of $16.87B supports balance-sheet flexibility.
| Trailing P/E | 75.09× |
| Forward P/E | 16.30× |
| Price / Sales | 7.28× |
| Price / Book | -78.92× |
| Gross margin | 72.8% |
| Operating margin | 40.0% |
| Profit margin | 9.8% |
| Free cash flow | $16.87B |
ABBV — Growth Outlook
Growth outlook for AbbVie Inc. (ABBV) depends on demand trends in Drug Manufacturers - General and the company's ability to convert revenue into sustainable earnings.
- Revenue growth of 10.2% indicates strong top-line momentum.
- Earnings growth of 2.9% year-over-year supports improving profitability.
- Price is 1.6% below the 52-week high.
ABBV — Competitive Position
AbbVie Inc. (ABBV) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Drug Manufacturers - General.
- Market capitalization of $468.43B places ABBV among mega-cap peers.
- Gross margin near 72.8% may reflect pricing power or favorable mix.
ABBV — Strengths
Strengths for AbbVie Inc. (ABBV) inferred from public financial metrics:
- Revenue growth of 10.2% year-over-year.
- Earnings growth of 2.9% year-over-year.
- Gross margin of 72.8% supports competitive unit economics.
- Positive free cash flow ($16.87B).
- Dividend yield of 2.6% for income-oriented holders.
- Mega Cap scale ($468.43B) may provide distribution and funding advantages.
ABBV — Weaknesses
Weaknesses and pressure points for AbbVie Inc. (ABBV) based on available data:
- Elevated trailing P/E (75.09×) limits valuation margin of safety.
ABBV — Opportunities
- Sustained revenue growth (10.2%) could support multiple expansion if margins hold.
- Dividend yield of 2.6% appeals to total-return investors.
- Positive free cash flow enables reinvestment, debt reduction, or shareholder returns.
- Forward earnings multiple below trailing P/E — potential earnings acceleration ahead.
ABBV — Risks
- Rich valuation (P/E 75.09×) increases downside if growth slows.
ABBV — Summary
AbbVie Inc. (ABBV) is a mega-cap Healthcare company focused on Drug Manufacturers - General, listed on NYQ. Last price $265.08 with market cap $468.43B. Trailing P/E 75.09×. Revenue grew 10.2% year-over-year per public data. Notable strengths include revenue growth of 10.2% year-over-year. Key watch items include elevated trailing p/e (75.09×) limits valuation margin of safety. Review free estimates and earnings pages for ABBV; upgrade for institutional ownership and live headlines.
Start Free — open ABBV in Vest Terminal
Access live data, filings, ownership, and analysis for AbbVie Inc..
AbbVie Inc. FAQ
What does AbbVie Inc. (ABBV) do?
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruv…
What is ABBV's P/E ratio?
AbbVie Inc. has a trailing P/E of 75.09× based on publicly available market data.
Does ABBV pay a dividend?
Indicated dividend yield: 2.6%. Confirm ex-dates and payout history in Vest Terminal.
What sector is ABBV in?
AbbVie Inc. is classified in Healthcare (Drug Manufacturers - General) on NYQ.
What is ABBV's market capitalization?
Approximate market cap: $468.43B.
What are the main risks for ABBV?
Key risks include elevated valuation, among factors on this page.
What are the strengths of ABBV?
Potential positives include revenue growth of 10.2% year-over-year, earnings growth of 2.9% year-over-year.
Where can I get analyst estimates for ABBV?
Public analyst price targets and consensus for AbbVie Inc. are on the free /stocks/abbv/estimates page. Deeper estimate history and models are available in Vest Terminal.